AU2001278734A1 - Method of extensive culture of antigen-specific cytotoxic t cells - Google Patents
Method of extensive culture of antigen-specific cytotoxic t cellsInfo
- Publication number
- AU2001278734A1 AU2001278734A1 AU2001278734A AU7873401A AU2001278734A1 AU 2001278734 A1 AU2001278734 A1 AU 2001278734A1 AU 2001278734 A AU2001278734 A AU 2001278734A AU 7873401 A AU7873401 A AU 7873401A AU 2001278734 A1 AU2001278734 A1 AU 2001278734A1
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- cells
- specific cytotoxic
- extensive culture
- extensive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000247072 | 2000-08-16 | ||
| JP2000-247072 | 2000-08-16 | ||
| PCT/JP2001/007032 WO2002014481A1 (en) | 2000-08-16 | 2001-08-15 | Method of extensive culture of antigen-specific cytotoxic t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001278734A1 true AU2001278734A1 (en) | 2002-02-25 |
Family
ID=18737246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001278734A Abandoned AU2001278734A1 (en) | 2000-08-16 | 2001-08-15 | Method of extensive culture of antigen-specific cytotoxic t cells |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7816134B2 (en) |
| EP (1) | EP1312670A4 (en) |
| JP (1) | JP4231688B2 (en) |
| KR (1) | KR100715926B1 (en) |
| CN (1) | CN1222612C (en) |
| AU (1) | AU2001278734A1 (en) |
| TW (1) | TWI235764B (en) |
| WO (1) | WO2002014481A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001278734A1 (en) * | 2000-08-16 | 2002-02-25 | Takara Bio Inc. | Method of extensive culture of antigen-specific cytotoxic t cells |
| JP4949607B2 (en) * | 2001-08-15 | 2012-06-13 | タカラバイオ株式会社 | Antigen-specific cytotoxic T cell expansion culture method |
| KR100786054B1 (en) * | 2002-03-25 | 2007-12-17 | 다카라 바이오 가부시키가이샤 | Method for producing cytotoxic lymphocytes |
| EA012520B1 (en) * | 2003-08-22 | 2009-10-30 | Такара Био Инк. | METHOD FOR OBTAINING CYTOTOXIC LYMPHOCYTES |
| EP1920774A4 (en) * | 2005-07-29 | 2008-09-24 | Suntory Ltd | COMPOSITION CONTAINING FUCOIDAN OR FUCOIDAN HYDROLYSAT AND AN IMMUNOSTIMULATING SUBSTANCE |
| KR101279172B1 (en) | 2005-08-17 | 2013-06-27 | 다카라 바이오 가부시키가이샤 | Method of producing lymphocytes |
| KR101408565B1 (en) * | 2005-09-30 | 2014-06-17 | 다카라 바이오 가부시키가이샤 | Method of manufacturing T cell population |
| US8216837B2 (en) | 2006-06-09 | 2012-07-10 | Takara Bio Inc. | Method of producing lymphocytes |
| KR100896747B1 (en) | 2007-05-30 | 2009-05-11 | 동아대학교 산학협력단 | Composition for inducing maturation of dendritic cells containing fucoidan or its analogs |
| KR100947821B1 (en) | 2008-01-09 | 2010-03-15 | 차의과학대학교 산학협력단 | Differentiation method of mesenchymal stem cells into osteoblasts and medium for differentiation |
| US9206394B2 (en) | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
| SI2400298T1 (en) * | 2010-05-28 | 2013-11-29 | F. Hoffmann-La Roche Ag | Single B-cell cultivation method and specific antibody production |
| WO2013176197A1 (en) * | 2012-05-22 | 2013-11-28 | 国立大学法人 東京大学 | Method for producing antigen-specific t cells |
| CN103013914B (en) * | 2012-12-13 | 2014-12-03 | 吉林省拓华生物科技有限公司 | Method for in-vitro culture of killer T cells |
| SI3421997T1 (en) * | 2012-12-28 | 2020-10-30 | Cellestis Limited | A cell mediated immune response assay |
| CN107789647B (en) * | 2016-09-05 | 2021-02-02 | 上海赛伦生物技术股份有限公司 | Method for inactivating virus in animal serum or plasma |
| EP3870218A1 (en) * | 2018-10-26 | 2021-09-01 | Istituto Oncologico Veneto IOV-IRCCS | Hyaluronic acid as a natural adjuvant for protein and peptide-based vaccines |
| CN113416700B (en) * | 2021-07-09 | 2023-04-11 | 天晴干细胞股份有限公司 | Efficient factor-secreting NK cell amplification method and application thereof |
| CN118524845A (en) * | 2021-11-11 | 2024-08-20 | 株式会社KJ Bio | T cell differentiation modulators and compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2561131B2 (en) * | 1988-06-30 | 1996-12-04 | 寳酒造株式会社 | Cell adhesion activity polypeptide |
| US5198423A (en) * | 1989-05-26 | 1993-03-30 | Takara Shuzo Co., Ltd. | Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin |
| US5188959A (en) * | 1989-09-28 | 1993-02-23 | Trustees Of Tufts College | Extracellular matrix protein adherent t cells |
| US6821778B1 (en) * | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
| DE4412794A1 (en) * | 1994-04-14 | 1995-12-14 | Univ Ludwigs Albert | Process for producing dendritic cells, cells thus obtained and containers for carrying out this process |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6692964B1 (en) * | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) * | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| ATE292689T1 (en) * | 1995-05-04 | 2005-04-15 | Us Navy | IMPROVED METHODS FOR TRANSFECTION OF T-CELLS |
| US6734014B1 (en) * | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| ATE476496T1 (en) * | 1996-03-04 | 2010-08-15 | Calyx Bio Ventures Inc | MODIFIED RAPID DEVELOPMENT METHOD ('MODIFIED-REM') FOR THE IN VITRO PRODUCTION OF T-LYMPHOCYTES |
| WO1997032970A1 (en) * | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes |
| AU728557B2 (en) | 1996-09-23 | 2001-01-11 | Ontogeny, Inc. | Hematopoietic stem cells and methods for generating such cells |
| AU6140998A (en) | 1997-01-31 | 1998-08-25 | Epimmune, Inc. | Peptides and peptide-loaded antigen presenting cells for the activation of ctl |
| AU2001278734A1 (en) * | 2000-08-16 | 2002-02-25 | Takara Bio Inc. | Method of extensive culture of antigen-specific cytotoxic t cells |
| JP4949607B2 (en) * | 2001-08-15 | 2012-06-13 | タカラバイオ株式会社 | Antigen-specific cytotoxic T cell expansion culture method |
-
2001
- 2001-08-15 AU AU2001278734A patent/AU2001278734A1/en not_active Abandoned
- 2001-08-15 KR KR1020037002249A patent/KR100715926B1/en not_active Expired - Fee Related
- 2001-08-15 EP EP01956894A patent/EP1312670A4/en not_active Withdrawn
- 2001-08-15 US US10/344,534 patent/US7816134B2/en not_active Expired - Fee Related
- 2001-08-15 CN CNB018174663A patent/CN1222612C/en not_active Expired - Fee Related
- 2001-08-15 JP JP2002519609A patent/JP4231688B2/en not_active Expired - Fee Related
- 2001-08-15 WO PCT/JP2001/007032 patent/WO2002014481A1/en not_active Ceased
- 2001-08-16 TW TW090120130A patent/TWI235764B/en not_active IP Right Cessation
-
2007
- 2007-04-23 US US11/790,025 patent/US20080166325A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7816134B2 (en) | 2010-10-19 |
| WO2002014481A1 (en) | 2002-02-21 |
| KR100715926B1 (en) | 2007-05-08 |
| CN1222612C (en) | 2005-10-12 |
| KR20030062317A (en) | 2003-07-23 |
| EP1312670A4 (en) | 2005-11-30 |
| US20080166325A1 (en) | 2008-07-10 |
| EP1312670A1 (en) | 2003-05-21 |
| JP4231688B2 (en) | 2009-03-04 |
| US20040115809A1 (en) | 2004-06-17 |
| CN1469923A (en) | 2004-01-21 |
| TWI235764B (en) | 2005-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001278734A1 (en) | Method of extensive culture of antigen-specific cytotoxic t cells | |
| AU2001286202A1 (en) | Method of culturing mesenchymal stem cells | |
| AU2001294520A1 (en) | Methods and compositions for increasing protein yield from a cell culture | |
| AU5090200A (en) | Culture chamber | |
| AU2002319780A1 (en) | Alternative compositions and methods for the culture of stem cells | |
| AU3867400A (en) | Methods of using bioelastomers | |
| AU1796601A (en) | Methods of preparing electrochemical cells | |
| AU2002336930A1 (en) | Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture | |
| AU1236801A (en) | Activation of hcv-specific t cells | |
| AU2001271502A1 (en) | Methods and compositions for isolating biologically active antibodies | |
| AU2001250036A1 (en) | Microdroplet cell culture technique | |
| AU2001280149A1 (en) | Stem cell culture medium and culture method by using the same | |
| AU2001235452A1 (en) | Cell culture media | |
| AU2002221665A1 (en) | Garage shaped biogas fermenter for the methanisation of biomasse | |
| AU2001233502A1 (en) | Pancreatic islet cell growth factors | |
| AU2002235728A1 (en) | Method for generating insulin-secreting cells suitable for transplantation | |
| AU2001290319A1 (en) | Fuel cell and method for preparation thereof | |
| AU2001227175A1 (en) | Method for thermal transformation of biomass | |
| AU2001246949A1 (en) | Process of culturing algae | |
| AU2001236718A1 (en) | Bioreactor and related method | |
| AU2001290321A1 (en) | Method of producing fuel cell | |
| GB9904773D0 (en) | Culture of mycobacteria | |
| AU3373300A (en) | Method of modifying cytotoxic cells and uses thereof | |
| AU2002211537A1 (en) | Culture of goblet cells | |
| AU3243600A (en) | Improved method of culturing t cells |